Edition:
United States

Teleflex Inc (TFX.N)

TFX.N on New York Stock Exchange

275.48USD
20 Jul 2018
Change (% chg)

$-1.92 (-0.69%)
Prev Close
$277.40
Open
$277.86
Day's High
$278.50
Day's Low
$275.17
Volume
35,531
Avg. Vol
91,155
52-wk High
$288.75
52-wk Low
$201.32

Latest Key Developments (Source: Significant Developments)

Teleflex Reports Q4 Revenue Rose 15.8 Pct To $595.1 Mln
Thursday, 22 Feb 2018 06:30am EST 

Feb 22 (Reuters) - Teleflex Inc ::TELEFLEX REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS; PROVIDES 2018 GUIDANCE.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $9.55 TO $9.75 FROM CONTINUING OPERATIONS.SEES FY 2018 GAAP EARNINGS PER SHARE $7.10 TO $7.20 FROM CONTINUING OPERATIONS.Q4 ADJUSTED EARNINGS PER SHARE $2.44 FROM CONTINUING OPERATIONS.Q4 GAAP LOSS PER SHARE $0.92 FROM CONTINUING OPERATIONS.Q4 REVENUE ROSE 15.8 PERCENT TO $595.1 MILLION.‍2018 GUIDANCE RANGE FOR GAAP REVENUE GROWTH OF 14% TO 15%​.‍2018 GUIDANCE RANGE FOR CONSTANT CURRENCY REVENUE GROWTH OF 12% TO 13%​.Q4 EARNINGS PER SHARE VIEW $2.40, REVENUE VIEW $601.2 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $9.64, REVENUE VIEW $2.42 BILLION -- THOMSON REUTERS I/B/E/S.DECREASE IN Q4 GAAP DILUTED EPS FROM CONTINUING OPERATIONS IS DUE TO $107.9 MILLION OF TAX EXPENSE REFLECTING IMPACT OF TAX CUTS AND JOBS ACT.  Full Article

Neotract Announces FDA Clearance Of Expanded Indications For Urolift System
Tuesday, 20 Feb 2018 06:30am EST 

Feb 20 (Reuters) - Teleflex Inc ::NEOTRACT ANNOUNCES FDA CLEARANCE OF EXPANDED INDICATIONS FOR UROLIFT® SYSTEM.NEOTRACT - EXPANDED INDICATIONS MEAN PATIENTS WITH OBSTRUCTIVE MEDIAN LOBE, AS YOUNG AS 45 NOW ELIGIBLE TO GET TREATMENT WITH UROLIFT FOR BPH SYMPTOMS.  Full Article

Teleflex Signs New Agreement With Healthtrust For Respiratory Heaters & Accessories
Tuesday, 12 Dec 2017 06:45am EST 

Dec 12 (Reuters) - Teleflex Inc ::TELEFLEX SIGNS NEW AGREEMENT WITH HEALTHTRUST FOR RESPIRATORY HEATERS & ACCESSORIES.TELEFLEX - AGREEMENT COVERS CO'S FULL LINE OF ACTIVE HUMIDIFICATION, NON INVASIVE VENTILATION, HIGH FLOW NASAL CANNULA THERAPY PRODUCTS.  Full Article

Teleflex announces pricing of $500 mln senior notes offering
Thursday, 16 Nov 2017 05:00pm EST 

Nov 16 (Reuters) - Teleflex Inc :Teleflex Incorporated announces pricing of $500 million senior notes offering.Teleflex Inc - ‍Priced offering of $500.0 million aggregate principal amount of 4.625% senior notes due 2027 at an issue price of 100.000%​.  Full Article

Teleflex announces public offering of $500 mln of senior notes
Thursday, 16 Nov 2017 08:00am EST 

Nov 16 (Reuters) - Teleflex Inc :Teleflex Incorporated announces public offering of $500 million of senior notes.Teleflex Inc - ‍intends to use net proceeds from offering to repay approximately $491.2 million of borrowings under its revolving credit facility​.Teleflex Inc - ‍registered public offering of $500.0 million aggregate principal amount of senior notes due 2027​.  Full Article

Teleflex reports Q3 adjusted profit of $2.12/shr
Thursday, 2 Nov 2017 06:30am EDT 

Nov 2 (Reuters) - Teleflex Inc :Teleflex reports third quarter 2017 results.Q3 adjusted earnings per share $2.12 from continuing operations.Q3 GAAP earnings per share $1.70 from continuing operations.Q3 revenue $534.7 million versus I/B/E/S view $523.1 million.Q3 earnings per share view $2.00 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $8.30 to $8.40 from continuing operations.Sees FY 2017 GAAP earnings per share $5.61 to $5.66 from continuing operations.‍lowered 2017 guidance for GAAP diluted EPS from a range of $5.91 to $5.98 to a range of $5.61 to $5.66​.Raised 2017 guidance for adjusted diluted EPS from a range of $8.20 to $8.35 to a range of $8.30 to $8.40.Teleflex Inc- co raised its full year 2017 GAAP revenue growth guidance range from 11.5 percent to 13.0 percent to a range of 15.0 percent to 15.5 percent over the prior year.FY 2017 earnings per share view $8.29, revenue view $2.11 billion -- Thomson Reuters I/B/E/S.Teleflex Inc - ‍raised 2017 guidance range for constant currency revenue growth to a range of 14.25 percent to 14.75 percent​.  Full Article

Teleflex awarded group purchasing contract with Vizient for central venous catheters
Wednesday, 23 Aug 2017 06:45am EDT 

Aug 23 (Reuters) - Teleflex Inc :Teleflex awarded group purchasing contract with Vizient Inc for non-tunneled central venous catheters.Teleflex Inc - ‍Announced a new three year product category contract with Vizient Inc​.Teleflex Inc - ‍New agreement for non-tunneled central venous catheters, became effective August 1, 2017​.  Full Article

Arrow Seldinger Arterial Catheterization Device receives FDA market clearance - Teleflex Inc
Monday, 24 Jul 2017 06:45am EDT 

July 24 (Reuters) - Teleflex Inc :Teleflex Inc says that its Arrow Seldinger Arterial Catheterization Device received market clearance from U.S. Food And Drug Administration.Teleflex Inc - expects to launch Arrow Seldinger Arterial Catheterization Device in United States this year.  Full Article

Teleflex commences phase I clinical study of RePlas freeze-dried plasma
Monday, 15 May 2017 06:30am EDT 

May 15 (Reuters) - Teleflex Inc :Teleflex (TFX) announces commencement of phase i clinical study (FDP-1) of RePlas™ freeze-dried plasma.Teleflex inc- RePlas, a lyophilized fresh frozen plasma product, being developed in collaboration with U.S. Army medical materiel development activity.  Full Article

Teleflex Q1 adjusted earnings per share $1.80 from continuing operations
Thursday, 4 May 2017 06:30am EDT 

May 4 (Reuters) - Teleflex Inc ::Teleflex reports first quarter 2017 results.Q1 adjusted earnings per share $1.80 from continuing operations.Q1 gaap earnings per share $0.87 from continuing operations.Q1 revenue $487.9 million versus I/B/E/S view $472.7 million.Q1 earnings per share view $1.69 -- Thomson Reuters I/B/E/S.Sees fy 2017 gaap earnings per share $5.59 to $5.66 from continuing operations.Teleflex - reaffirms 2017 guidance range for gaap revenue growth of 10.0 pct to 11.5 pct and constant currency revenue growth of 12.5 pct to 14.0 pct.Teleflex - raises 2017 guidance for adjusted diluted eps from a range of $8.00 to $8.15 to a range of $8.05 to $8.23.Fy2017 earnings per share view $8.10, revenue view $2.07 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Teleflex Reaffirms Previously Provided Financial Guidance For 2018

* TELEFLEX SAYS REAFFIRMS PREVIOUSLY PROVIDED FINANCIAL GUIDANCE FOR 2018